Middleton Gary
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Immunother Adv. 2020 Dec 18;1(1):ltaa010. doi: 10.1093/immadv/ltaa010. eCollection 2021 Jan.
In this first in a series of 'Trials Watch' articles, we briefly review a highly selected set of clinical trials that are currently recruiting or about to open to recruitment in melanoma, the disease first transformed by the introduction of immune checkpoint blockade inhibitors (ICI). We place equal emphasis on phase I/II studies investigating the activity of biologically compelling novel immunotherapeutics, and on randomised trials of ICI with and without novel agents, as these latter studies optimise the standard-of-care use of ICI, and determine whether novel agents become part of the approved therapeutic armamentarium. We do not consider here combination therapy with other checkpoint antagonists or agonists besides combination of anti-PD-1/PD-L1 monoclonal antibodies (mAbs) with anti-CTLA4 mAbs, as these will be reviewed in a subsequent article in this series. A glossary of agents to be discussed is found at the end of this article.
在这一系列“试验观察”文章的第一篇中，我们简要回顾了一组经过精心挑选的临床试验，这些试验目前正在招募患者或即将在黑色素瘤领域开展招募工作。黑色素瘤是因引入免疫检查点阻断抑制剂（ICI）而首次发生转变的疾病。我们同样重视研究具有生物学吸引力的新型免疫疗法活性的I/II期研究，以及ICI联合或不联合新型药物的随机试验，因为这些后期研究优化了ICI的标准治疗应用，并确定新型药物是否会成为获批治疗药物库的一部分。除了抗PD-1/PD-L1单克隆抗体（mAb）与抗CTLA4 mAb联合使用外，我们在此不考虑与其他检查点拮抗剂或激动剂的联合治疗，因为这将在本系列的后续文章中进行综述。本文末尾提供了将讨论的药物术语表。
